Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038207 · ClinicalTrials.gov registry record · Phase 2
Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00038207: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00038207 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00038207, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if treatment with the drug liposomal vincristine can shrink or slow the growth of the patient's cancer. The safety of this drug will also be studied.
Interventions
- DRUG Liposomal Vincristine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2000-06 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038207
The ClinicalTrials.gov registry entry for NCT00038207 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Liposomal Vincristine is the first listed.
NCT00038207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038207 about?
NCT00038207 is a clinical study titled "Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies". The goal of this clinical research study is to learn if treatment with the drug liposomal vincristine can shrink or slow the growth of the patient's cancer. The safety of this drug will also be studied.
What is the current status of trial NCT00038207?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2000-06. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00038207?
The interventions under investigation include: Liposomal Vincristine (DRUG).
Who is sponsoring clinical trial NCT00038207?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.